Table 3: Demographic and clinical data in 65 patients with CV event and 279 patients without CV events.
Characteristics | With CV events (n. 65) | Without CV events (n. 279) | p | |
Demographics | F/M | 43/22 | 224/55 | 0.02 |
Mean age at onset, years (SD) | 54.4 (12.3) | 45.7 (15.6) | < 0.0001a | |
Mean age at baseline, years (SD) | 60.8 (10) | 54.3 (11.9) | < 0.0001a | |
Mean drug exposure duration, years (SD) | 14.3 (6.9) | 18.4 (8.8) | 0.04a | |
Mean RA duration at last observation, years (SD) | 18.7 (7.1) | 18.4 (8.8) | 0.84a | |
Anti-TNF alfa exposure, n. (%) | 21/65 (32) | 65/214 (30.3) | 0.76 | |
Comorbidities | Arterial hypertension (%) | 17/37 (45.9) | 41/156 (26.2) | 0.032 |
Smoking habits (%) | 10/35 (28.5) | 37/156 (23.7) | 0.56 | |
Dyslipidemia (%) | 24/65 (36.9) | 17/153 (11.1) | < 0.0001 | |
Familiar CV disease (%) | 45/65 (69.2) | 113/279 (40.5) | < 0.0001 | |
Diabetes (%) | 10/43 (23.2) | 7/156 (4.4) | < 0.0001 | |
CAD (%) | 4/38 (10.5) | 4/279 (1.4) | 0.005 | |
Mean n. Framingham risk factors at the CV event (SD) | < 0.0001b | 5.98 (7.2) | < 0.0001b | |
CV-related drugs | B blockers (%) | 29 (44.6) | 44/278 (15.8) | < 0.0001 |
Ace inhibitors (%) | 29 (44.6) | 42/278 (15.1) | < 0.0001 | |
Diuretics (%) | 25 (38.4) | 48/278 (17.2) | < 0.0001 | |
Anti-platelets (%) | 39 (60) | 53/279 (18.9) | < 0.0001 | |
Oral anti-coagulants (%) | 12 (18.4) | 7/279 (2.5) | < 0.0001 | |
Statins (%) | 18 (27.6) | 25/279 (8.9) | < 0.0001 |
a = Unpaired t test; b = Mann-Whitney test.